Lipocine (NASDAQ:LPCN) Earns Hold Rating from Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Lipocine (NASDAQ:LPCN) in a research note issued on Wednesday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Lipocine Price Performance

Shares of LPCN stock opened at $3.15 on Wednesday. The business has a fifty day moving average of $4.40 and a 200 day moving average of $4.59. Lipocine has a 1 year low of $2.96 and a 1 year high of $11.79. The firm has a market capitalization of $16.85 million, a price-to-earnings ratio of -4.14 and a beta of 1.23.

Institutional Investors Weigh In On Lipocine

A hedge fund recently raised its stake in Lipocine stock. Geode Capital Management LLC boosted its holdings in shares of Lipocine Inc. (NASDAQ:LPCN) by 6.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 57,464 shares of the specialty pharmaceutical company’s stock after buying an additional 3,248 shares during the quarter. Geode Capital Management LLC owned 1.07% of Lipocine worth $280,000 at the end of the most recent reporting period. 9.11% of the stock is currently owned by institutional investors and hedge funds.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.